Analysts’ Downgrades for May 10th (ABEV, ABOS, ABSI, ADSE, AKBA, AKRO, ALCO, ALGS, ALLK, ALRM)

Analysts’ downgrades for Tuesday, May 10th:

Ambev (NYSE:ABEV) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Companhia de Bebidas das Americas (AmBev), based in São Paulo, is engaged in producing, distributing and selling beer, carbonated soft drinks and other non-alcoholic and non-carbonated products in many countries across the Americas. It maintains an agreement with PepsiCo International, Inc. to bottle, sell and distribute Pepsi products in Brazil and in other Latin American countries, including Lipton Ice Tea, Gatorade, H2OH!, Propel and Frutzzz. AmBev conducts its operations through three business units: Latin America North, Latin America South and Canada. Latin America North includes its operations in Brazil, where it operates two divisions: beer sales and carbonated soft drinks and non-alcoholic non-carbonated sales; and its operations in its Hispanic Latin America Operations, excluding Latin America South, operations. Latin America South includes its Quinsa operations in the countries of Argentina, Bolivia, Paraguay, Uruguay and Chile. Canada, represented by Labatt, includes domestic sales in Canada. “

Acumen Pharmaceuticals (NASDAQ:ABOS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company’s product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va. “

Absci (NASDAQ:ABSI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company’s Creation(TM) Platform involved in discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Absci Corporation is based in VANCOUVER, Wash. “

ADS-TEC Energy (NASDAQ:ADSE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “ADS-TEC Energy GmbH provides battery-buffered ultrafast charging technology. ADS-TEC Energy GmbH, formerly known as European Sustainable Growth Acquisition Corp., is based in NEW YORK. “

Akebia Therapeutics (NASDAQ:AKBA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Akero Therapeutics (NASDAQ:AKRO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company’s product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States. “

Alico (NASDAQ:ALCO) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Alico, Inc. is an agribusiness company operating in Central and Southwest Florida. The company is involved in various operations and activities including citrus fruit production, cattle ranching, sugarcane and sod production, and forestry. The company also leases land for farming, cattle grazing, recreation, and oil exploration. “

Aligos Therapeutics (NASDAQ:ALGS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif. “

Allakos (NASDAQ:ALLK) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. “

Alarm.com (NASDAQ:ALRM) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Alarm.com Holdings, Inc. offers interactive security solutions for home and business owners. The Company offers security systems which include image sensor, crash and smash protection, web control, mobile access and video monitoring. Alarm.com Holdings, Inc. is based in VIENNA, United States. “

Alto Ingredients (NASDAQ:ALTO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Alto Ingredients Inc. is a producer of specialty alcohols and essential ingredients. The company is focused on products which includes Health, Home & Beauty; Food & Beverage; Essential Ingredients and Renewable Fuels. Alto Ingredients Inc., formerly known as Pacific Ethanol Inc., is based in SACRAMENTO, Calif. “

AMC Entertainment (NYSE:AMC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “AMC Entertainment Holdings, Inc., operates as a theatrical exhibition company primarily in the United States and internationally. It owned or interests in theatres and screens. AMC Entertainment Holdings, Inc. is based in Leawood, Kansas. “

Diebold Nixdorf (NYSE:DBD) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating.

Receive News & Ratings for Ambev SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambev SA and related companies with MarketBeat.com's FREE daily email newsletter.